Using granulocyte–macrophage colony-stimulating factor (GM-CSF) as an adjuvant, mRNA direct cancer vaccines induce tumor-specific T-cell responses for tumor rejection by encoding cancer antigens, such as tumor-associated antigens (TAAs) and tumor-specific antigens. Here, CSF2 is linked to neoplasm.